- Home
- Equipment
- usa california
- tumor activity
Refine by
Tumor Activity Equipment Supplied In Usa California
15 equipment items found
Manufactured by:Senti Biosciences based inSouth San Francisco, CALIFORNIA (USA)
The product profile of SENTI-301 has the potential to promote expansion and persistence of NK cells, and activate and recruit the body’s own immune cells into the solid tumor microenvironment for enhanced anti-tumor activity. ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
Initial clinical data presented at the ASCO and ESMO 2018 Annual Meetings showed that CX-072 demonstrated tolerability and anti-tumor activity, while reducing activation of the immune system outside the tumor. Initial clinical translation data presented at SITC confirmed that CX-072 is unmasked, activated and has ...
Manufactured by:Nkarta, Inc. based inSouth San Francisco, CALIFORNIA (USA)
OX40 costimulatory domain, CD3ζ signaling moiety, membrane bound ...
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
BridgeBio has entered into a strategic collaboration with Helsinn to co-develop and co-commercialize a potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) with the hope of providing an effective new therapy for patients with difficult-to-treat tumors. Our approach has demonstrated monotherapy activity, reducing ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
B7H3 belongs to the B7 family of immune checkpoint inhibitors and is expressed on a wide range of solid and hematologic malignancies. B7H3 is an important mediator of tumor angiogenesis and metastasis, and higher expression is associated with a poor prognosis for patients. We are developing FT573, an investigational, universal, off-the-shelf NK cell cancer immunotherapy derived ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
In addition to CD38 targeting in multiple myeloma, targeting of other tumor-associated cell-surface proteins has been clinically investigated. Of these antigens, the TNF-superfamily member B-cell Maturation Antigen (BCMA) is among the most researched. Several clinical trials in multiple myeloma have shown promising initial results targeting BCMA with CAR T cells. ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
Probody therapeutics are designed to outsmart cancer by exploiting the unique conditions of the tumor microenvironment to more effectively localize treatment to the tumor, while limiting activity in healthy tissues. These novel therapies are designed to take advantage of high levels of protease activity in the ...
Manufactured by:Brooklyn ImmunoTherapeutics (BTX) based inSan Diego, CALIFORNIA (USA)
IRX-2 is a human-derived mixed cytokine product containing more than 29 cytokines that promote or enhance a complex immune response. Scientists are developing IRX-2 as a cancer immunotherapy. IRX-2 is administered as a subcutaneous injection around lymph node beds near the tumor target. IRX-2 is produced under cGMP (current good manufacturing process) conditions following stimulation of a ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
CAR T-cell therapy has recently emerged as a revolutionary and potentially curative therapy for patients with certain hematologic malignancies, including refractory cancers. In 2017, two CAR T-cell therapies were approved by the FDA for the treatment of relapsed / refractory B-cell precursor acute lymphoblastic leukemia (ALL) and relapsed / refractory diffuse large B-cell lymphoma (DLBCL). While ...
Manufactured by:Qualigen Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
This potentially enables a differentiated, RAS-targeted strategy for inhibiting the MAPK, PI3K, and TOR pathways that are implicated in cancer cell proliferation, survival, and differentiation (see figure). RAS itself acts as a “hub” that activates multiple effector pathways and blocking any single pathway is ineffective for many tumor types, ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
T cells engineered with chimeric antigen receptors (CARs) have shown exceptional promise as a potentially curative therapy for patients with certain hematologic malignancies. While most researchers and clinical investigators continue to focus on the development of autologous or allogeneic CAR T-cell therapies, we are developing CAR NK cell product candidates created from clonal master engineered ...
Manufactured by:Adicet Bio based inMenlo Park, CALIFORNIA (USA)
The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet to be proven. The cell platform and novel targeting approaches Adicet is developing are aimed at harnessing the tumor specific immunity of gamma delta T cells. The Company believes that ...
Manufactured by:Qualigen Therapeutics, Inc. based inCarlsbad, CALIFORNIA (USA)
Qualigen licensed the G4 selective transcription inhibitor platform from University College London (UCL) in 2022. The licensed technology comprises lead compound QN-302 (formerly SOP1812) and back-up compounds that target regulatory regions of cancer genes that down-regulate gene expression in multiple cancer pathways. Developed by Dr. Stephen Neidle and his group at UCL, the G4 binding concept ...
by:LIXTE Biotechnology Holdings, Inc. based inPasadena, CALIFORNIA (USA)
Pre-clinical studies showed that LB-100 alone inhibits a spectrum of human cancers but when combined with standard cytotoxic drugs and/or radiation, LB-100 potentiates their effectiveness against hematologic and solid tumor cancers without enhancing toxicity. In addition, given at very low doses in animal models of cancer, LB-100 markedly increased the effectiveness of a PD-1 blocker, one of the ...
Manufactured by:DxTerity Diagnostics Inc. based inRancho Dominguez, CALIFORNIA (USA)
Autoimmune diseases need analysis tools that go beyond superficial symptoms to recognize the distinct immune system activity of each patient. Modular transcriptome repertoire analysis 1, also known as modular genomics, shows tremendous promise for improving the characterization of patients with autoimmune diseases such as Systemic Lupus Erythematosus (SLE)7, Multiple Sclerosis (MS), Inflammatory ...